Federal Register / Vol. 66, No. 86 / Thursday, May 3, 2001 / Notices 22235

construction, renovation, the lease of

passenger vehicles, the development of

major software applications, or

supplanting current applicant

expenditures.

The National Center for Injury

Prevention and Control of CDC will

provide information on submitting

applications via the Rape Prevention

and Education Version of the Grant

Application and Reporting System

(RPE–GARS).

DATES: Awards will begin on or about

October 1, 2001, and will be made for

a 12-month budget period within a

project period of up to five years.

Comments are due June 4, 2001.

ADDRESSES: Interested persons are

invited to comment on the proposed

program. All comments received on or

before June 4, 2001 will be considered

before the final program announcement

is published. Address comments to:

Wendy Watkins, Division of Violence

Prevention, National Center for Injury

Prevention and Control, Centers for

Disease Control and Prevention (CDC),

4770 Buford Highway, NE, Mailstop K–

58, Atlanta, GA 30341–3724, Telephone

(770) 488–1567, Internet address:

dmw7@cdc.gov.

FOR FURTHER INFORMATION CONTACT:

Wendy Watkins, Division of Violence

Prevention, National Center for Injury

Prevention and Control, Centers for

Disease Control and Prevention (CDC),

4770 Buford Highway, NE, Mailstop K–

58, Atlanta, GA 30341–3724, Telephone

(770) 488–1567, Internet address:

dmw7@cdc.gov.

Dated: April 27, 2001.

Joseph R. Carter,

Associate Director for Management and

Operations,, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 01–11068 Filed 5–2–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Request for Input on Vaccine

Financing

AGENCY: Centers for Disease Control and

Prevention (CDC), Department of Health

and Human Services (DHHS).

ACTION: Notice and request for public

comment.

SUMMARY: The National Vaccine

Advisory Committee (NVAC) Work

Group on the Introduction of New

Vaccines seeks input on issues that may

be barriers to the optimal

implementation of new vaccines. The

work group is evaluating how vaccine

financing affects the standard of care for

different population subgroups.

Vaccine financing can impact specific

population subgroups differentially in

terms of access and supply of new

vaccines. The process by which the

public and private sector purchase and

distribute vaccines may differ in

important ways. The public sector plays

a major role in the financing of pediatric

vaccine, but it plays a smaller role in the

financing of adult vaccines. The timing

of public purchase may depend on

specific advisory group

recommendations as well as specific

state budgets. The eligibility for public

and private payer programs may also

vary.

We are asking partner organizations

and groups to submit their items on the

pluses and minuses of the current

vaccine financing system. In addition to

identifying potential barriers to the

optimal implementation of vaccines due

to vaccine financing, possible solutions

to these problems are requested. The

information gathered from the partners

will be used as the basis for a meeting

to develop options for the NVAC to

consider.

DATES: Comments and information must

be submitted by May 31, 2001.

ADDRESSES: Comments and information

regarding Vaccine Financing should be

submitted to the National Vaccine

Program Office, Attn: Introduction of

New Vaccines, Centers for Disease

Control and Prevention, Mailstop D–66,

1600 Clifton Road, NE., Atlanta, Georgia

30333; Federal Express Address: 200 E.

Ponce de Leon Avenue, Decatur,

Georgia 30030; fax: 404–687–6687; email: nvpo@cdc.gov.

FOR FURTHER INFORMATION CONTACT: The

National Vaccine Program Office, Attn:

Introduction of New Vaccines, Centers

for Disease Control and Prevention,

Mailstop D–66, 1600 Clifton Road, NE.,

Atlanta, Georgia 30333; Federal Express

Address: 200 E. Ponce de Leon Avenue,

Decatur, Georgia 30030; fax: 404–687–

6687; e-mail: nvpo@cdc.gov.

Dated: April 27, 2001.

Joseph R. Carter,

Associate Director for Management and

Operations, Centers for Disease Control and

Prevention.

[FR Doc. 01–11067 Filed 5–2–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 01N–0183]

Elanco Animal Health, A Div. of Eli Lilly

& Co. et al.; Withdrawal of Approval of

NADAs

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is withdrawing

approval of 13 new animal drug

applications (NADAs) listed below at

the request of the sponsor. In a final rule

published elsewhere in this issue of the

Federal Register, FDA is amending the

animal drug regulations by removing the

portions reflecting approval of the

NADAs.

DATES: Withdrawal of approval is

effective May 14, 2001.

FOR FURTHER INFORMATION CONTACT:

Pamela K. Esposito, Center for

Veterinary Medicine (HFV–210), Food

and Drug Administration, 7500 Standish

Pl., Rockville, MD 20855, 301–827–

5593.

SUPPLEMENTARY INFORMATION: The

following sponsors have requested that

FDA withdraw approval of the NADAs

listed below because the products are no

longer manufactured or marketed:

Sponsor NADA Number Product (Drug) 21 CFR Cite Affected

(Sponsor Drug Labeler Code)

Elanco Animal Health, A Div. of Eli Lilly & Co.,

Lilly Corporate Center, Indianapolis, IN 46285.

NADA 12–585 Tylan Injectable (tylosin tartrate).522.2640b (000986)

............................................................................. NADA 15–207 Hyferdex Injection (iron

dextran complex).

522.1183(c) (000986)